PARK2-9 CL22
The cell line is not validated yet.
UKWi008-A-1
General
Cell Line |
|
| hPSCreg name | UKWi008-A-1 |
| Cite as: | UKWi008-A-1 |
| Alternative name(s) |
PARK2-9 CL22
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
MICCNi002-A (ADHD Stem Cell Study_subject 5, clone A1, hiPSC_03 affected sibling) Donor diseases: attention deficit hyperactivity disorder MICCNi002-B (ADHD Stem Cell Study_subject 5, hiPSC_03 affected sibling, clone A16) Donor diseases: attention deficit hyperactivity disorder TMPi006-A (MR-001 x3, MR001 x3, MR-001 c3, MR001 c3) Donor diseases: Attention Deficit Hyperactivity Disorder TMPi006-B (MR001 x15, MR-001 x15, MR-001 c15, MR001 c15) Donor diseases: Attention Deficit Hyperactivity Disorder TMPi009-A (MR014 c12.1.1, MR-014 c12, MR-014 c12.1.1, MR014 c12) Donor diseases: Attention Deficit Hyperactivity Disorder |
| Last update | 12th November 2025 |
| User feedback | |
Provider |
|
| Generator | Universitätsklinikum Würzburg (UKW) |
External Databases |
|
| BioSamples | SAMEA120318364 |
General Information |
|
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
| Subclone of | |
Donor Information
General Donor Information |
|
| Sex | female |
| Ethnicity | Caucasian |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
External Databases (Donor) |
|
| BioSamples | SAMEA120318363 |
Ethics
Also have a look at the ethics information for the parental line
UKWi008-A
.
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
|
The source cell information can be found in the parental cell line
UKWi008-A.
|
|
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Sendai virus |
| Is reprogramming vector detectable? |
No |
| Methods used |
RT-PCR
|
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
Unknown |
| Derived under GMP? |
Unknown |
| Available as clinical grade? |
Unknown |
Culture Conditions
| Surface coating | Matrigel/Geltrex | ||||||
| Feeder cells |
irradiated Mouse Embryonic Fibroblasts |
||||||
| Passage method |
Enzyme-free cell dissociation
ReLeSR™ (by STEMCELL Technologies)
|
||||||
| O2 Concentration | 20 % | ||||||
| CO2 Concentration | 5 % | ||||||
| Medium |
Other medium:
Base medium: StemMACS™ PSC-Brew XF, human
Main protein source: Serum concentration: 0 % Supplements
|
||||||
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
||||||
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
||||||
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| POU5F1 (OCT-4) |
Yes |
|||||
| SSEA-4 |
Yes |
|
Morphology pictures
Differentiation Potency
In vitro directed differentiation
Protocol or reference
In vitro directed differentiation
Protocol or reference
In vitro directed differentiation
Protocol or reference
Genotyping
Karyotyping (Cell Line) |
|
Other Genotyping (Cell Line) |
Genetic Modification
| Genetic modifications not related to a disease |
|
Login to share your feedback, experiences or results with the research community.